ArriVent BioPharma, Inc. - 10-Q Filing

ArriVent BioPharma filed its quarterly report for March 31, 2026, disclosing financial and operational updates including equity incentives, collaborative arrangements with companies like Alphamab Biopharmaceuticals Co. Ltd., Aarvik Pharmaceuticals Inc., Lepu Biopharma, and Shanghai Allist Pharmaceuticals Co. Ltd., as well as a $75 million underwritten public offering on July 3, 2025.

SEC EDGAR · May 11, 2026, 20:10 UTC

Tickers: $AVBP

Read the full article at SEC EDGAR

More Regulatory news

First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC